BR112014009210A2 - método para a redução da vermelhidão facial cutânea - Google Patents

método para a redução da vermelhidão facial cutânea

Info

Publication number
BR112014009210A2
BR112014009210A2 BR112014009210A BR112014009210A BR112014009210A2 BR 112014009210 A2 BR112014009210 A2 BR 112014009210A2 BR 112014009210 A BR112014009210 A BR 112014009210A BR 112014009210 A BR112014009210 A BR 112014009210A BR 112014009210 A2 BR112014009210 A2 BR 112014009210A2
Authority
BR
Brazil
Prior art keywords
reducing skin
facial redness
skin facial
redness
reducing
Prior art date
Application number
BR112014009210A
Other languages
English (en)
Inventor
Clapp Arthur
Andres Philippe
j scherer Warren
Original Assignee
Galderma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Sa filed Critical Galderma Sa
Publication of BR112014009210A2 publication Critical patent/BR112014009210A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
BR112014009210A 2011-10-19 2012-10-12 método para a redução da vermelhidão facial cutânea BR112014009210A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161548844P 2011-10-19 2011-10-19
PCT/IB2012/002500 WO2013057579A2 (en) 2011-10-19 2012-10-12 Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors

Publications (1)

Publication Number Publication Date
BR112014009210A2 true BR112014009210A2 (pt) 2017-04-18

Family

ID=47631462

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014009210A BR112014009210A2 (pt) 2011-10-19 2012-10-12 método para a redução da vermelhidão facial cutânea

Country Status (12)

Country Link
US (1) US9744168B2 (pt)
EP (1) EP2768502A2 (pt)
JP (1) JP2014530846A (pt)
KR (1) KR20140091543A (pt)
CN (1) CN103889417A (pt)
AU (1) AU2012324543B2 (pt)
BR (1) BR112014009210A2 (pt)
CA (1) CA2850273A1 (pt)
IL (1) IL231820A0 (pt)
MX (1) MX2014004383A (pt)
RU (1) RU2014119879A (pt)
WO (1) WO2013057579A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120076738A1 (en) * 2010-09-28 2012-03-29 Michael Graeber Combination treatment for dermatological conditions
ES2796871T3 (es) * 2014-06-11 2020-11-30 Epi Health Llc Formulaciones de oximetazolina estabilizadas y sus usos
AU2017338319A1 (en) * 2016-10-07 2019-05-02 Micreos Human Health B.V. Vasoconstrictive and antibacterial combination treatment for rosacea
KR102122980B1 (ko) * 2018-12-28 2020-06-18 한국프라임제약주식회사 들깨 잎 추출물을 유효성분으로 함유하는 갱년기 관련 안면홍조 완화용 조성물

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
DE2436883C2 (de) 1974-07-29 1985-08-22 Schering AG, 1000 Berlin und 4709 Bergkamen Benzimidazol-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE2436882A1 (de) 1974-07-29 1976-02-19 Schering Ag Neue oxyphenylbutazon-derivate und ihre herstellung
DE2632678C2 (de) 1976-07-16 1986-02-27 Schering AG, 1000 Berlin und 4709 Bergkamen 6α-Fluor-12α-Halogen-Kortikoide und Verfahren zu ihrer Herstellung
NZ185295A (en) 1976-10-04 1980-04-28 Schering Ag 9-chloroprednisolone derivatives and pharmaceutical compositions
US4285967A (en) 1978-06-30 1981-08-25 Estee Lauder Inc. Cosmetic preparation for reducing redness of blemishes
US4908387A (en) 1988-06-06 1990-03-13 The Regents Of The University Of California Use of beta2 antagonists in the treatment of inflammatory diseases, in particular, rheumatoid arthritis
IL92351A (en) 1988-11-29 1994-02-27 Allergan Inc Irvine Optimal aqueous solutions containing stabilized chlorine acid and inorganic salt
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
EP0723447B1 (en) 1993-10-13 2002-12-11 Allergan, Inc. Use of (2-imidazolin-2-ylamino) quinoxaline derivatives
US6117871A (en) 1993-12-17 2000-09-12 The Procter & Gamble Company 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
CA2154979A1 (en) 1995-07-28 1997-01-29 Kenneth T. Armstrong Topical phenylephrine preparation
US5910312A (en) 1996-10-09 1999-06-08 Ideal Ideas, Inc. Acne treatment composition with vasoconstrictor
ES2239466T3 (es) 1998-10-20 2005-09-16 Omeros Corporation Solucion de irrigacion y metodo de inhibicion del dolor y de la inflamacion.
SE9901295D0 (sv) 1999-04-13 1999-04-13 Jan Hedner Sätt och medel för att förebygga, behandla och diagnostisera kardiovaskulära komplikationer hos patienter med obstruktiv sömnapné
EP1206282A1 (en) 1999-08-19 2002-05-22 Lavipharm S.A. Film forming polymers, methods of use, and devices and applications thereof
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
NZ521185A (en) 2000-07-14 2005-02-25 Allergan Inc Compositions containing alpha-2-adrenergic agonist components
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US6680062B2 (en) 2001-10-05 2004-01-20 Color Access, Inc. Anti-irritating rosacea treatment
US7345065B2 (en) 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
ES2647618T3 (es) * 2004-05-25 2017-12-22 Galderma Pharma S.A. Compuestos, formulaciones y procedimientos para tratar o prevenir trastornos inflamatorios de la piel
US20090061020A1 (en) 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
NZ586302A (en) 2007-12-21 2013-03-28 Galderma Lab Inc Pre-surgical treatment using brimonidine applied topically to reduce bleeding or bruising
KR20110017365A (ko) 2008-05-30 2011-02-21 페어필드 클리니컬 트라이얼즈 엘엘씨 피부 염증 및 변색을 위한 방법 및 조성물
WO2009152344A2 (en) 2008-06-11 2009-12-17 Comgenrx, Inc. Combination therapy using phosphodiesterase inhibitors
US20110104083A1 (en) 2009-10-30 2011-05-05 Intratus, Inc. Methods and cosmetic preparations for the sustained delivery of therapeutic agents to the eye
CN106038476B (zh) 2010-03-26 2020-04-17 盖尔德马研究及发展公司 安全和有效治疗红斑的改进的方法和组合物

Also Published As

Publication number Publication date
EP2768502A2 (en) 2014-08-27
AU2012324543B2 (en) 2017-08-10
KR20140091543A (ko) 2014-07-21
JP2014530846A (ja) 2014-11-20
AU2012324543A1 (en) 2014-05-01
RU2014119879A (ru) 2015-11-27
CA2850273A1 (en) 2013-04-25
WO2013057579A3 (en) 2013-07-04
IL231820A0 (en) 2014-05-28
US20140343067A1 (en) 2014-11-20
MX2014004383A (es) 2014-11-12
US9744168B2 (en) 2017-08-29
CN103889417A (zh) 2014-06-25
WO2013057579A2 (en) 2013-04-25

Similar Documents

Publication Publication Date Title
BR112015005749A2 (pt) sitema e método para produzir cosméticos
DK3117861T3 (da) Grænseflade omfattende en rullende næsebrodel
HK1178308A1 (en) System and method for improving head positioning
BR112014007128A2 (pt) cabeça de barbeador
BR112014003798A2 (pt) método para fabricar um composto, e, composto
BR112013031209A2 (pt) método para produção de hidrógéis
BR112014008603A2 (pt) tablete, e, método para produzir um tablete
EP2676201A4 (en) DATABASE AND METHOD FOR CONTROLLING THE ACCESS TO THE DATABASE
EP2747836A4 (en) FACE REJUVENATION DEVICE
BR112014008652A2 (pt) aplicador de produto cosmético e método para a produção de um aplicador de produto cosmético
DK2732131T3 (da) Positioneringsfremgangsmåde
TWI563280B (en) Positioning method
BR112014004592A2 (pt) processo para efetuar uma oxidação em um suprimento
EP2730311A4 (en) FACIAL MASSAGE DEVICE
BR112013022559A2 (pt) cartão, e, método para fabricar um cartão
BR112014028726A2 (pt) método para alisar o cabelo
BR112013030423A2 (pt) método para produção de biocoque
BRDI7103744S (pt) Configuração aplicada em barbeador
GB2505106B (en) Method and arrangement for short coherence holography
BR112014009551A2 (pt) método para encapsular um ativo de cuidado pessoal
HK1200910A1 (zh) 化妝品的評價方法
BR112013023465A2 (pt) método para produzir l-cisteína
BR112013031360A2 (pt) método para produzir um composto, e, composto
BR112015004829A2 (pt) método para a cimentação dentro de locais confinados
HK1202297A1 (en) Methods for treating acne

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2483 DE 07-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.